Catheter ablation compared with a sham procedure for atrial fibrillation in very elderly people
Tests catheter ablation against a sham procedure in very elderly people with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Anzhen Hospital
- Trial code
- NCT07403760
- Record updated
- 6 July 2026
- Original description
The WISER-AF trial is a multicenter, double-blind, sham-controlled, randomized controlled trial. It aims to evaluate the efficacy and safety of catheter ablation compared to a sham procedure in improving the quality of life (SF-36 score) in very elderly patients (aged ≥80 years) with symptomatic atrial fibrillation over a 6-month follow-up period.Read full original descriptionShow less
Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly (WISER-AF)
The WISER-AF trial is a multicenter, double-blind, sham-controlled, randomized controlled trial. It aims to evaluate the efficacy and safety of catheter ablation compared to a sham procedure in improving the quality of life (SF-36 score) in very elderly patients (aged ≥80 years) with symptomatic atrial fibrillation over a 6-month follow-up period.
Inclusion: Age ≥ 80 years; Documented paroxysmal or persistent atrial fibrillation by ECG or Holter within 6 months prior to enrollment; Symptomatic AF (including palpitations, chest tightness, fatigue, dizziness, blackouts, dyspnea); Voluntary participation and signed informed consent.
Exclusion: History of prior AF ablation; Prior Left Atrial Appendage Occlusion (LAAO); NYHA Class IV heart failure; Acute myocardial infarction, cardiac surgery, or PCI within the past 1 year; AF secondary to reversible causes (e.g., post-surgery, infection, hyperthyroidism); Moderate to severe hepatic failure (Child-Pugh B-C); Inability to cooperate due to dementia or severe mental disorder; Renal failure stage 4-5 (eGFR <30 ml/min/1.73m2) or continuous dialysis; Long-standing persistent AF (duration > 1 year); Left atrial anteroposterior diameter > 6 cm; Severe mitral stenosis; Presence of left atrial thrombus; Contraindication to anticoagulation; Life expectancy < 1 year.